Home / Knowledge Centre /

The impact of the European Pharmacopeia Regulations for peptides during the change of manufacturer at late phase

The regulations controlling the use of synthetic peptides as therapeutics has changed significantly over the last number of years with peptides now being viewed as closer to small molecules in terms of process control, structural characterisation and individual impurity limits. This can become challenging as peptides move through clinical development, and further complicated if a new manufacturer is tasked with preparing material that is of a higher quality than previously produced, with little information as to how the peptides were manufactured previously.
Submit your details to download the full article

View Resource
Almac Logo

Almac API, Chemical Development, Analytical & Solid State Services

Almac Sciences provides integrated services from development to commercial scale of advanced intermediates and Active Pharmaceutical Ingredients (API).

We provide a range of services for small molecules (including highly potent) and peptides. We have a proven track record of saving time and cost through the integration of our services and application of innovative biocatalysis and technology solutions.

Learn More

We offer a full suite of analytical testing for a range of different product types including small molecules, peptides, biologics, conjugates, potent and controlled substances.

Our vast pool of scientific knowledge can help to overcome the analytical challenges that typically arise during drug development.

Learn More

Please complete this form to view the Article

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies